Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma R Haas, R Mohle, S Fruhauf, H Goldschmidt, B Witt, M Flentje, ... | 590 | 1994 |
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) B Wassmann, H Pfeifer, N Goekbuget, DW Beelen, J Beck, M Stelljes, ... Blood 108 (5), 1469-1477, 2006 | 462 | 2006 |
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid A Kuendgen, C Strupp, M Aivado, A Bernhardt, B Hildebrandt, R Haas, ... Blood 104 (5), 1266-1269, 2004 | 334 | 2004 |
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry J Neukirchen, WM Schoonen, C Strupp, N Gattermann, C Aul, R Haas, ... Leukemia research 35 (12), 1591-1596, 2011 | 311 | 2011 |
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia A Kuendgen, M Schmid, R Schlenk, S Knipp, B Hildebrandt, C Steidl, ... Cancer 106 (1), 112-119, 2006 | 296 | 2006 |
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation HH Euler, AM Marmont, A Bacigalupo, S Fastenrath, P Dreger, ... | 289 | 1996 |
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells S Geyh, S Öz, RP Cadeddu, J Fröbel, B Brückner, A Kündgen, R Fenk, ... Leukemia 27 (9), 1841-1851, 2013 | 281 | 2013 |
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation T Schroeder, A Czibere, U Platzbecker, G Bug, L Uharek, T Luft, ... Leukemia 27 (6), 1229-1235, 2013 | 281 | 2013 |
Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. R Haas, AD Ho, U Bredthauer, S Cayeux, G Egerer, W Knauf, W Hunstein Experimental Hematology 18 (2), 94-98, 1990 | 269 | 1990 |
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary … U Germing, B Hildebrandt, M Pfeilstöcker, T Nösslinger, P Valent, ... Leukemia 19 (12), 2223-2231, 2005 | 224 | 2005 |
Thalidomide for the treatment of patients with myelodysplastic syndromes C Strupp, U Germing, M Aivado, E Misgeld, R Haas, N Gattermann Leukemia 16 (1), 1-6, 2002 | 221 | 2002 |
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions—a … T Schroeder, E Rachlis, G Bug, M Stelljes, S Klein, NK Steckel, D Wolf, ... Biology of Blood and Marrow Transplantation 21 (4), 653-660, 2015 | 219 | 2015 |
The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans F Zohren, D Toutzaris, V Klärner, HP Hartung, B Kieseier, R Haas Blood, The Journal of the American Society of Hematology 111 (7), 3893-3895, 2008 | 218 | 2008 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia RF Schlenk, S Fröhling, F Hartmann, JT Fischer, A Glasmacher, ... Leukemia 18 (11), 1798-1803, 2004 | 215 | 2004 |
No increase in age-specific incidence of myelodysplastic syndromes U Germing, C Strupp, A Kundgen, D Bowen, C Aul, R Haas, ... Haematologica 89 (8), 905-910, 2004 | 208 | 2004 |
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or … A Kuendgen, S Knipp, F Fox, C Strupp, B Hildebrandt, C Steidl, ... Annals of hematology 84, 61-66, 2005 | 202 | 2005 |
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes U Germing, C Strupp, A Kuendgen, S Isa, S Knipp, B Hildebrandt, ... Haematologica 91 (12), 1596-1604, 2006 | 200 | 2006 |
Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. S Hohaus, H Goldschmidt, R Ehrhardt, R Haas Experimental hematology 21 (4), 508-514, 1993 | 193 | 1993 |
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells U Steidl, R Kronenwett, UP Rohr, R Fenk, S Kliszewski, C Maercker, ... Blood, The Journal of the American Society of Hematology 99 (6), 2037-2044, 2002 | 191 | 2002 |
Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. R Möhle, S Murea, M Kirsch, R Haas Experimental hematology 23 (14), 1535-1542, 1995 | 190 | 1995 |